TABLE 2.
Variable | Patient | Non-CRRT (n = 11) | CRRT (n = 6) | p | a Adjusted p-value |
---|---|---|---|---|---|
Cmax (ng/mL) | Patient 1 | 434.71 | 411.17 | 0.129 | b – |
Patient 2 | 228.83 | 713.65 | |||
Patient 3 | 269.97 | 330.52 | |||
Patient 4 | 271.46 | 573.16 | |||
Patient 5 | 366.97 | 411.65 | |||
Patient 6 | 400.47 | 590.55 | |||
Patient 7 | 477.28 | – | |||
Patient 8 | 481.50 | – | |||
Patient 9 | 492.05 | – | |||
Patient 10 | 504.08 | – | |||
Patient 11 | 541.91 | – | |||
Mean ± SD | 406.29 ± 108.00 | 505.11 ± 143.84 |
Cmax, Peak concentration; CRRT, continuous renal replacement therapy.
p: Tigecycline concentration was compared between the two groups of patients using unpaired t-test.
Adjusted p-value: Tigecycline concentration was compared between the two groups of patients using multivariate linear regression analysis model, adjusted for variables retained after bootstrap selection.
Multivariate linear regression was not performed for Cmax because there is no variable retained after bootstrap selection.